The first patient has been enrolled in the RE-SPECT ESUS phase III study to investigate the efficacy and safety of dabigatran etexilate (Boehringer Ingelheim) for the prevention of recurrent embolic stroke of undetermined source (ESUS). RE-SPECT ESUS aims to include 6,000 patients in 35 countries.
For the first time, the Multicentre randomised clinical trial of endovascular treatment for acute ischaemic stroke in the Netherlands (MR CLEAN) has shown better outcomes in favour of intervention in patients with acute ischaemic stroke.
More than 70 teams composed of 568 students and entrepreneurs have been accepted to compete in the Neuro Startup Challenge, an open innovation competition designed to bring promising brain-related inventions to market. The challenge has teams competing to commercialise 16 National Institutes of Health-conceived and -developed inventions involving therapeutics, diagnostics, prognostics, and medical devices for a range of brain diseases.
Three-year outcomes from an ongoing clinical trial suggest that high-dose immunosuppressive therapy followed by transplantation of a person’s own blood-forming stem cells may induce sustained remission in some people with relapsing-remitting multiple sclerosis (RRMS). The trial is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and conducted by the NIAID-funded Immune Tolerance Network (ITN).
BrainScope Company has announced the publication of an independent study that demonstrated the potential clinical utility of its traumatic brain injury technology to identify acute stroke in the hospital Emergency Department setting. The results of this study, “Identification of Acute Stroke Using Quantified Brain Electrical Activity” were published in the peer-reviewed journal Academic Emergency Medicine authored by investigators from University Hospitals Case Medical Center, New York University School of Medicine, and The Johns Hopkins University School of Medicine, USA.
New research at the University of Cincinnati Neuroscience Institute has shown that spreading depolarisations can be measured by the placement of electroencephalograph (EEG) electrodes on the scalp. Head of the research team, Jed Hartings (research associated professor, Department of Neurosurgery, University of Cincinnati Neuroscience Institute, USA) speaks to NeuroNews about the discovery and its potential to change current practice.
Intrinsic Imaging has been awarded a clinical trial to study an interventional medical device designed for the prevention of pulmonary emboli.
The US FDA has cleared the Enroute transcarotid neuroprotection system (Silk Road Medical) for marketing. The system is for use during carotid artery stenting procedures and is the first one designed to access the carotid arteries through an incision in the neck, instead of the groin. It uses a blood flow reversal system to capture pieces of the blockage dislodged during the procedure.
InspireMD has received CE mark approval for its new CGuard RX rapid exchange system for its MicroNet covered carotid stent technology. Concurrently, the company announced positive six-month follow up data from its CGuard CARENET (Carotid embolic protection study using MicroNet) trial at the LINC meeting in Leipzig, Germany.
Vascular News has learnt that the SPACE 2 (Stent-protected angioplasty in asymptomatic carotid stenosis vs. endarterectomy) study has been halted due to persistently low recruitment rates. This decision to halt SPACE 2 comes just over a year after changes were made to the study protocol in an attempt to rectify the same problem.
Two new clinical trials on the treatment of stroke (ESCAPE and EXTEND IA) demonstrate that neurointerventional surgery significantly increases the number of patients who are able to live independently without major neurological disabilities. The ESCAPE study, published 11 February in the New England Journal of Medicine, also shows that neurointerventional surgery reduces stroke mortality by 50%.
Medtronic plc has announced that it has received US Food and Drug Administration (FDA) approval for its Pipeline Flex embolisation device. Available through a limited US launch in the coming weeks, Medtronic’s latest-generation flow diversion device represents an unrivalled advancement in large and giant brain aneurysm treatment.
A new computer programme allows interventionalists to assess blood flow in real-time while they are using flow-diverter devices to treat intracranial aneurysms, suggests a pilot study presented at the 27th annual International Symposium on Endovascular Therapy (ISET, 31 January–5 February, Hollywood, USA).
The use of flow-diverting stents to treat intracranial aneurysms appears safe and highly successful. Recently, however, there have been reports of ischaemic complications occurring in brain territories supplied by the parent artery in which the stent is placed and in brain regions fed by small arterial branches whose ostia are covered by the stent.
Initial experience with PulseRider (Pulsar Vascular) has shown the device to be safe and effective as an adjunct in the treatment of bifurcation aneurysms arising at the basilar apex or carotid terminus according to a report of the first three cases in the USA published in the Journal of NeuroInterventional Surgery.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos